Actualités Xortx Therapeutics Inc - XRTX | Actions TSX Venture Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

XORTX Strengthens Executive Team

CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Announces Presentation at the Rare and Genetic Disease Summit

CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats...

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Initiates Precision Medicine Program

CALGARY, Alberta, Oct. 09, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease...

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Xortx Therapeutics Inc (XRTX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

XRTX Actualités

XORTX Strengthens Executive Team

XORTX Announces Presentation at the Rare and Genetic Disease Summit

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Initiates Precision Medicine Program

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

XORTX to Present at BIO International Convention 2024

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Xortx Therapeutics Inc (XRTX) Actualités

Xortx Therapeutics Inc (XRTX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

XRTX Actualités

XORTX Strengthens Executive Team

XORTX Announces Presentation at the Rare and Genetic Disease Summit

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Initiates Precision Medicine Program

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

XORTX to Present at BIO International Convention 2024

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application